225 related articles for article (PubMed ID: 1675013)
1. Surrogate markers for AIDS treatment.
Jacobson M
Nurs Times; 1991 May 29-Jun 4; 87(22):49. PubMed ID: 1675013
[No Abstract] [Full Text] [Related]
2. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.
Fahey JL; Taylor JM; Detels R; Hofmann B; Melmed R; Nishanian P; Giorgi JV
N Engl J Med; 1990 Jan; 322(3):166-72. PubMed ID: 1967191
[TBL] [Abstract][Full Text] [Related]
3. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine.
Jacobson MA; Bacchetti P; Kolokathis A; Chaisson RE; Szabo S; Polsky B; Valainis GT; Mildvan D; Abrams D; Wilber J
BMJ; 1991 Jan; 302(6768):73-8. PubMed ID: 1671651
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.
Dis Markers; 1990; 8(3):164-5. PubMed ID: 2125538
[No Abstract] [Full Text] [Related]
5. [ Biological criteria for prediction of the clinical course leading to AIDS].
Salmon D; Couroucé AM; Doinel C; Fine JM; Kaplan C; Lambin P; Lefrère JJ; Rouger P; Salmon C
Rev Fr Transfus Hemobiol; 1990 Dec; 33(6):407-14. PubMed ID: 1981002
[No Abstract] [Full Text] [Related]
6. Immune activation markers and AIDS prognosis.
Osmond DH; Shiboski S; Bacchetti P; Winger EE; Moss AR
AIDS; 1991 May; 5(5):505-11. PubMed ID: 1677808
[TBL] [Abstract][Full Text] [Related]
7. Behaviour of different clinical, immunological and serological parameters observed in a group of HIV positive patients during a 12 month treatment period with zidovudine.
Crocchiolo PR; Lizioli A; Arcidiacono I; Cantaluppi P; Filippi C; Sobatti D; Bedarida G; D'Agostino F; Cambie G; Nardella ML
Boll Ist Sieroter Milan; 1990 Jun; 69(2):423-30. PubMed ID: 1983798
[TBL] [Abstract][Full Text] [Related]
8. Alpha 1-acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine (ZDV).
Oie S; Jacobson MA; Abrams DI
J Acquir Immune Defic Syndr (1988); 1993 May; 6(5):531-3. PubMed ID: 8097790
[No Abstract] [Full Text] [Related]
9. Serum levels of soluble CD8, neopterin, beta 2-microglobulin and p24 antigen as indicators of disease progression in children with AIDS on zidovudine therapy.
Siller L; Martin NL; Kostuchenko P; Beckett L; Rautonen J; Cheng SC; Wara DW
AIDS; 1993 Mar; 7(3):369-73. PubMed ID: 8097095
[TBL] [Abstract][Full Text] [Related]
10. [Lymphocyte subpopulations, neopterin, and beta-2-microglobulin: relationship with clinical stage, risk of progression to AIDS and presence of active infection in HIV infection].
Antón F; Labarga P; Pinilla J; Soto MJ; Leoz A; del Cura J; Borque L; Milazzo A
Enferm Infecc Microbiol Clin; 1993; 11(7):373-7. PubMed ID: 8104488
[TBL] [Abstract][Full Text] [Related]
11. Effect of azidothymidine (AZT) on HIV P24 antigen, beta 2-microglobulin, neopterin, soluble CD8, soluble interleukin-2 receptor and tumor necrosis factor alpha levels in patients with AIDS-related complex or AIDS.
Reddy MM; McKinley G; Englard A; Grieco MH
Int J Immunopharmacol; 1990; 12(7):737-41. PubMed ID: 2127261
[TBL] [Abstract][Full Text] [Related]
12. Neopterin and beta-2 microglobulin levels in asymptomatic HIV infection: the predictive value of combining markers.
Harrison NA; Skidmore SJ
J Med Virol; 1990 Oct; 32(2):128-33. PubMed ID: 2126281
[TBL] [Abstract][Full Text] [Related]
13. Markers of risk in HIV-1.
Krämer A; Biggar RJ; Goedert JJ
N Engl J Med; 1990 Jun; 322(26):1886. PubMed ID: 1971915
[No Abstract] [Full Text] [Related]
14. [The natural history and laboratory parameters of HIV infection].
Brühwiler J; Lüthy R; Joller-Jemelka HI; Ledergerber B; Fierz W; Siegenthaler W; Grob PJ
Dtsch Med Wochenschr; 1989 Jun; 114(26):1015-20. PubMed ID: 2500318
[TBL] [Abstract][Full Text] [Related]
15. Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection.
Godfried MH; van der Poll T; Mulder JW; Weverling GJ; Endert E; Lange JM; Sauerwein HP
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):531-9. PubMed ID: 8548332
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of serum beta 2-microglobulin in HIV infection.
Krämer A; Goedert JJ; Wachter H; Fuchs D
Lancet; 1992 Aug; 340(8815):371. PubMed ID: 1379663
[No Abstract] [Full Text] [Related]
17. [HIV infection and T-lymphocyte behavior: results of a study in Palermo].
Cangelosi C; Giardina RA; Pecoraro G; Marcianò R; Vitale MG; Gullotti A; Caronia F; Spanò C
Ann Ig; 1989; 1(1-2):45-50. PubMed ID: 2483080
[TBL] [Abstract][Full Text] [Related]
18. The initial immune response to HIV and immune system activation determine the outcome of HIV disease.
Sheppard HW; Ascher MS; McRae B; Anderson RE; Lang W; Allain JP
J Acquir Immune Defic Syndr (1988); 1991; 4(7):704-12. PubMed ID: 1675678
[TBL] [Abstract][Full Text] [Related]
19. [Blood antigens and specific anti-core and anti-envelope antibodies as markers of the course of HIV infection].
Sorice F; Vullo V; Cirelli A; Catania S; Mastroianni CM; Contini C; Delia S
Boll Ist Sieroter Milan; 1989; 68(2):115-21. PubMed ID: 2562362
[TBL] [Abstract][Full Text] [Related]
20. Serum p24 antigen levels in untreated and zidovudine-treated HIV-1 infected subjects.
Mulder JW; Lange JM; de Wolf F; Houweling JT; Bakker M; Coutinho RA; Goudsmit J
Neth J Med; 1990 Aug; 37(1-2):4-10. PubMed ID: 2120599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
